SMOC-1 是心肌梗死后心脏破裂的内源性保护分子
本研究对急性心肌梗死合并心脏破裂患者与未破裂患者血浆进行蛋白质组学分析,发现 SMOC-1 在破裂组显著上调最明显。动物模型显示心肌细胞来源的 SMOC-1 通过结合成纤维细胞 TGF-βR1 并招募 EPRS 激活 Smad 通路,促进纤维化与胶原成熟。增强 SMOC-1 通路有望减少心脏破裂并降低心梗相关死亡。
要点
- 心肌梗死后心脏破裂缺乏有效干预,SMOC-1 是潜在保护靶点。
- 心肌细胞短暂上调并分泌 SMOC-1,高峰在心梗后 1 天。
- SMOC-1 通过 TGF-βR1/EPRS/Smad 通路促进修复性纤维化。
核心结论
- 心肌细胞来源 SMOC-1 的短暂上调与分泌是对严重缺血损伤的内源性促纤维化和抗破裂反应。
- 该天然保护机制不足以完全防止心脏破裂,增强 SMOC-1 通路是减轻心脏破裂及降低 AMI 相关死亡的有前景策略。
研究设计与样本
- 研究纳入急性心肌梗死患者血浆样本、动物模型血浆及 AMI 小鼠左心室组织。
- 采用无偏蛋白质组学分析鉴定心脏破裂相关蛋白,并通过功能丧失和功能获得动物模型探索因果与机制。
主要发现
- 蛋白质组学显示与未破裂患者相比,心脏破裂患者中 9 个蛋白显著上调,24 个蛋白显著下调。
- SMOC-1(分泌型模块化钙结合蛋白 1)是上调最显著的蛋白,扩展患者队列和动物模型验证了这一发现。
- 时间进程研究显示 SMOC-1 表达短暂升高,AMI 后 1 天达峰,一周内回到基线。
- 免疫学与细胞特异性分析确定心肌细胞是 AMI 后 SMOC-1 的主要来源。
- 心肌细胞特异性 SMOC-1 敲除使心梗后心脏破裂发生率翻倍并降低生存率。
临床怎么用
- 可考虑将 SMOC-1 通路作为 AMI 后心脏破裂风险干预的探索方向,但原文未提供可直接用于临床的阈值或剂量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cardiac rupture is a catastrophic complication of acute myocardial infarction (AMI), with poorly understood molecular mechanisms and no available therapeutic interventions. METHODS: Plasma samples were obtained from patients with AMI and animal models, while left ventricular tissue was collected from AMI mice. An unbiased proteomics analysis identified proteins significantly altered in patients with AMI with cardiac rupture. To explore causal relationships and underlying mechanisms, we used loss- and gain-of-function animal models. RESULTS: Proteomics analysis revealed that 9 proteins were significantly upregulated and 24 proteins were significantly downregulated in patients with AMI with cardiac rupture compared with those without. Among these, SMOC-1 (secreted modular calcium-binding protein 1) was the most significantly upregulated protein. Validation in extended patient cohorts and animal models confirmed these findings. A time-course study revealed that SMOC-1 expression was transiently elevated, peaking 1 day after AMI and returning to baseline within a week. Immunological and cell-specific analyses identified cardiomyocytes as the predominant source of SMOC-1 in response to AMI. Surprisingly, cardiomyocyte-specific SMOC-1 knockout doubled the incidence of post-AMI cardiac rupture and reduced survival, while adeno-associated virus serotype 9-mediated SMOC-1 overexpression significantly decreased cardiac rupture rates. Mechanistic studies revealed that cardiomyocyte-derived SMOC-1 supports fibrosis by activating fibroblasts, enhancing collagen synthesis, and promoting collagen maturation, all of which are critical for the formation of reparative scars. SMOC-1 was shown to bind TGF-βR1 (transforming growth factor β receptor 1) in fibroblasts, recruiting EPRS (glutamyl-prolyl-tRNA synthetase) to form a signaling complex that activates the Smad pathway. Inhibiting EPRS abolished the profibrotic effects of SMOC-1. CONCLUSIONS: Our study provides the first evidence that the transient upregulation and secretion of cardiomyocyte-derived SMOC-1 constitute an intrinsic profibrotic and antirupture response to severe ischemic injury. However, this natural protective mechanism is insufficient to fully prevent cardiac rupture, highlighting the potential of enhancing the SMOC-1 pathway as a promising therapeutic strategy to mitigate cardiac rupture and reduce AMI-associated mortality.
引用
- Gong, Li, Zhang, et al. Identification of Secreted Modular Calcium-Binding Protein 1 as a Novel Endogenous Protective Molecule Against Acute Myocardial Infarction-Induced Cardiac Rupture. Circulation. 2026. PMID: 42808155. doi:10.1161/CIRCULATIONAHA.126.079324
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。